Health Condition 1: E559- Vitamin D deficiency, unspecified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Sponsors
Stavya Spine Hospital and Research Institute
Eligibility
Inclusion criteria
Inclusion criteria: Any adult patient of either sex diagnosed or suffering from Osteoporosis T-score -2.5 and below as reported in past 3 months or at baseline Patient with no history of fragility fracture but DXA T-scores of less then -2.5 Patient with fragility fracture even if DXA T-scores of more than -2.5 Patient with imminent risk of fragility fracture or history of multiple fragility fractures Patients on any on-going management of anti-osteoporotic treatment
Exclusion criteria
Exclusion criteria: If the mechanism of injury was not low energy Patient of age less then 30 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measure patient satisfaction with osteoporotic treatments and FLS interventions compared to routine care over the study period and assess changes in patients quality of life using validated questionnairesTimepoint: Visit at 3 months, 6 months, 12 months, 18 months, and 24 months after enrolment | — |
Secondary
| Measure | Time frame |
|---|---|
| Measure the reduction in the incidence of new fractures in patients receiving osteoporotic treatments & managed through Fracture Liaison Services (FLS) compared to those receiving routine care. Assess the overall effectiveness of fracture liaison services in managing osteoporosis & preventing fractures Assess the change in bone mineral density (BMD) from baseline to the end of the study period in patients receiving osteoporotic treatments Evaluate the adherence to & persistence with prescribed osteoporotic treatments over the study period. Evaluate clinical outcomes such as the incidence of subsequent fractures, any adverse events, & other clinical or surrogate markers Collect & analyze data on demographic & reproductive characteristics, as well as risk factors for fractures, to identify any correlations with treatment outcomes over the study periodTimepoint: Visit 1 Screening Visits ( Up to 2 weeks), Visit 2 BaseLine (Day 0), Visit 3 Follow up (Week 24),Visit 4 Week 48) End of study | — |
Countries
India
Contacts
Public ContactDr Bharat R Dave
Stavya Spine Hospital And Research Institute
Outcome results
None listed